In the VALOR trial, brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared ...
The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...
Hidradenitis suppurativa is managed with biologics like adalimumab and secukinumab, approved for moderate-to-severe cases. Adalimumab, a TNF-α inhibitor, was FDA-approved in 2015, while secukinumab, ...
DUBLIN--(BUSINESS WIRE)--The "Biological Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Biological Drugs was estimated at ...
Tumour necrosis factor (TNF) inhibitors are more likely discontinued due to ineffectiveness in patients aged 16-24 years than in those aged 45-54 years. However, patients aged ≥ 75 years have an ...
The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...
FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback